Postpartum Hemorrhage (PPH) — New Guidelines 2025

Key Update: WHO Consolidated Guidelines 2025

🔴 Major New Changes

1. Revised Definition & Blood Loss Threshold for Intervention

• ≥ 300 mL of measured blood loss plus any abnormal vital sign (tachycardia or hypotension) → mandates immediate intervention rather than observation
• This replaces the previous ≥500 mL (vaginal) / ≥1000 mL (caesarean) thresholds as the sole diagnostic criteria

2. Objective Measurement of Blood Loss (NEW — Strongly Emphasized)

• Calibrated drapes are now recommended for all births to replace visual estimation
• Visual estimation consistently underestimates blood loss by 30–50%, contributing to delayed treatment
• FIGO issued dedicated 2025 recommendations (PMID: 40985490) on objective measurement as the standard of care
• Monitoring indicators: proportion of women with objectively measured blood loss is now a key output indicator

PREVENTION (Antenatal → Intrapartum)

Antenatal Prevention

Uterotonic Prophylaxis (3rd Stage) — Only ONE uterotonic to be used:

Important: TXA prophylaxis is now explicitly contraindicated for prevention despite its established role in treatment.

Other Preventive Measures

• Controlled cord traction: recommended where skilled attendants are present; not recommended without skilled attendants (revalidated)
• Active management of 3rd stage of labour remains the cornerstone
• Recognition of prolonged 2nd stage of labour is newly emphasized (EBCOG commentary)

DIAGNOSIS & Early Detection

• Objective blood loss quantification (calibrated drapes) at every birth — strong emphasis
• Trigger intervention at ≥300 mL measured loss + abnormal vital signs (new lower threshold)
• Real-time ultrasound to identify retained placenta, clots
• Vigilance for the 4 Ts: Tone (70–80%), Trauma, Tissue, Thrombin

TREATMENT

First-Line Bundle (Rec 29 — Revalidated with update)

1. Uterine massage (rapid institution)
2. Oxytocic agent administration
3. Tranexamic acid (TXA) 1 g IV — give early, within 3 hours of birth
4. IV fluids (resuscitation)
5. Examination of genital tract for lacerations
6. Escalation of care

Uterotonics for Treatment (step-up)

Tranexamic Acid

• TXA 1 g IV as part of the treatment bundle
• Give as early as possible, within 3 hours of birth onset
• If bleeding continues after 30 min, a second dose 1 g IV may be given
• NEW: TXA is NOT recommended for prophylaxis (only for active treatment)

Uterine Tamponade (for refractory atony)

• Bakri balloon / Foley catheter tamponade (Rec updated)
• Uterine packing with sterile gauze
• Rec 30: uterotonic for retained placenta only if PPH is present

Transfusion & Blood Products (if needed)

• Target Hb during active PPH resuscitation
• Early fibrinogen supplementation if coagulopathy suspected
• Cell salvage: reviewed by Cochrane 2024 (PMID: 39704317) — evidence emerging for operative settings

Surgical Escalation

• Selective uterine artery embolization (where facilities available)
• Laparotomy options:
  • Bilateral uterine/ovarian artery ligation
  • Internal iliac artery ligation
  • B-Lynch suture (compression suture)
  • Hysterectomy — last resort in life-threatening hemorrhage

SUPPORTIVE CARE & HEALTH SYSTEMS

• Uterotonic within 1 minute of birth — key output indicator
• Multiprofessional team training and simulation: newly emphasized (EBCOG commentary)
• Debriefing after PPH events
• Standardized protocols, checklists, and PPH care bundles at facility level
• Clear escalation pathways and monitoring indicators at facility, sub-national, and national levels

Recent Evidence (2024–2025)

Key Takeaways from 2025 Guidelines

1. Earlier intervention: ≥300 mL + abnormal vitals (not just ≥500 mL)
2. Objective measurement mandatory: calibrated drapes replace visual estimation
3. TXA for treatment (not prevention): give early in the treatment bundle
4. IV iron new recommendation: for iron-deficiency anaemia in pregnancy
5. Team training newly emphasized as a system-level priority
6. Single uterotonic for prophylaxis (no combination regimens)

⚠️ Guideline Alert: These are the 2025 WHO consolidated guidelines. Earlier guidelines (ACOG 2017, WHO 2012) defined PPH as ≥500 mL (vaginal) or ≥1000 mL (caesarean). The new lower threshold with vital sign integration represents a significant practice change.